CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 194 enrolled
Drug / intervention
SVT-15652 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03686397
NCT03686397Phase 3Completed

A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of SVT-15652 Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (Otomycosis).

Salvat·interventional·Posted Sep 26, 2018·Updated Dec 15, 2022

In Brief

A Phase 3 clinical trial evaluating SVT-15652 and Placebo for Otomycosis. Completed, enrolled 194 participants across 1 site.

Detailed Summary

Multicenter, randomized, 2-arm parallel-group, double blind, placebo-controlled study in patients suffering from Otomycosis. This study will compare the efficacy and safety of SVT-15652 otic solution to that of Placebo, when administering one vial twice daily during 14 days.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOtomycosis
CountriesSpain
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 26, 2018
Enrollment StartJun 9, 2020
Primary CompletionOct 19, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 7.8 years ago

Interventions

SVT-15652drug

1 vial twice daily

Placebodrug

1 vial twice daily